



# Artisan Sustainable Emerging Markets Fund

MONTHLY  
Commentary

Investor Class: ARTZX | Advisor Class: APDEX

As of 31 July 2022

## Commentary

Our portfolio has a positive performance QTD, outpacing the MSCI Emerging Markets Index. Emerging markets equities overall have declined slightly QTD, as they have been hampered by inflation pressures, slower global economic growth, tightening global financial conditions and currency weakness. India and Korea have been the benchmark's top contributors QTD while China has been the benchmark's primary detractor.

Estun Automation and MercadoLibre have been among our top relative contributors QTD. Estun Automation is a leading domestic Chinese robot producer. While market demand has been soft, Estun has been able to gain market share in China as foreign competitors have faced significant supply chain disruptions. Estun has also been able to increase its prices and trim costs. Longer term, we believe Estun's efforts to roll out new products, move into new product areas, push more component production to China and improve operating leverage will improve sales and margins.

Shares of MercadoLibre, Latin America's leading online commerce platform, have followed the general QTD improvement in technology stocks outside of China. While it faces some near-term headwinds—weaker economic growth, loan portfolio performance concerns and consumers returning to stores or spending more on services—we believe it is well-positioned. The company's comprehensive ecosystem gives it a sustainable competitive advantage and should enable it to capture market share.

Among our leading relative detractors QTD have been China Traditional Chinese Medicine and Zhuzhou CRRC Times Electric. China Traditional Chinese Medicine is the largest manufacturer of traditional Chinese medicine (TCM) granules in China. The government is forcing TCM formula standardization for more than 700 granules—selecting a manufacturer's standards to be adopted by the entire industry for each granule. Standardization has caused the CTM market to temporarily shrink and production costs to rise. While China Traditional Chinese Medicine's standards have been selected for half of the approximately 200 granules standardized so far, the selection of other manufacturers' standards has led the company to write down intellectual property values on some of its products. We believe the company will ultimately benefit as its standards will likely be selected for many more granules and standardization will likely cause industry consolidation.

Zhuzhou provides and integrates train-borne electrical systems for China's railway industry. Zhuzhou's railway has had no improvement in order activity due to China's severe COVID-related restrictions, although demand could improve as those restrictions are eased. We have been focused on Zhuzhou's non-rail business. It has been gaining market share in insulated gate bipolar transistors (IGBTs)—switches well suited for high-voltage applications such as power grids and electric vehicles. IGBTs are becoming a more important competitive advantage and long-term growth driver.

Volatility is to be expected in emerging markets, and it can be extreme at times—a natural part of what we believe is a superior growth opportunity over longer periods. We are maintaining our disciplined process and closely monitoring positions—including engagement with management teams—to adjust valuations and position size as we believe appropriate.

## Investment Results (%)

As of 31 July 2022	Average Annual Total Returns								
	MTD	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception	
Investor Class: ARTZX	0.70	0.70	-25.80	-29.47	-1.07	0.24	2.81	-0.45	
Advisor Class: APDEX	0.63	0.63	-25.85	-29.52	-1.10	0.23	2.80	-0.45	
MSCI Emerging Markets Index	-0.25	-0.25	-17.83	-20.09	0.90	0.95	2.84	1.04	

  

As of 30 June 2022	MTD	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception
Investor Class: ARTZX	-6.14	-12.44	-26.32	-32.40	-1.83	0.99	2.72	-0.50
Advisor Class: APDEX	-6.14	-12.44	-26.32	-32.40	-1.83	0.99	2.72	-0.50
MSCI Emerging Markets Index	-6.64	-11.45	-17.63	-25.28	0.57	2.18	3.06	1.06

Source: Artisan Partners/MSCI. Returns for periods less than one year are not annualized. Class inception: Investor (2 June 2008); Advisor (27 April 2022). For the period prior to inception, Advisor Class performance is the Investor Class's return for that period ("Linked Performance"). Linked Performance has not been restated to reflect expenses of the Advisor Class and the share class's returns during that period would be different if such expenses were reflected.

Past performance does not guarantee and is not a reliable indicator of future results. Investment returns and principal values will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than that shown. Call 800.344.1770 for current to most recent month-end performance. Performance may reflect agreements to limit a Fund's expenses, which would reduce performance if not in effect.

## Portfolio Details

	ARTZX	APDEX
Net Asset Value (NAV)	\$14.32	\$14.31
Inception	2 Jun 2008	27 Apr 2022
Expense Ratios (% Gross/Net)		
Semi-Annual Report 31 Mar 2022 <sup>1,2,3</sup>	1.58/1.32 <sup>4</sup>	—/—
Prospectus 30 Sep 2021 <sup>1,3,5</sup>	1.60/1.15	—/—
Prospectus 27 Apr 2022 <sup>1,3,6</sup>	—/—	1.43/1.05

<sup>1</sup>Net expenses reflect a contractual expense limitation agreement in effect through 31 Jan 2024. <sup>2</sup>Unaudited, annualized for the six-month period. <sup>3</sup>See prospectus for further details. <sup>4</sup>Expense limit was lowered during the period, effective 1 Mar 2022. <sup>5</sup>Restated to reflect a reduction in management fees, effective as of 1 Mar 2022. <sup>6</sup>Includes estimated expenses for the current fiscal year.

## Top 10 Holdings (% of total portfolio)

Taiwan Semiconductor Manufacturing Co Ltd (Taiwan)	9.9
Samsung Electronics Co Ltd (Korea)	7.1
Alibaba Group Holding Ltd (China)	3.9
Estun Automation Co Ltd (China)	3.7
E Ink Holdings Inc (Taiwan)	3.7
ICICI Bank Ltd (India)	3.4
Zhuzhou CRRC Times Electric Co Ltd (China)	3.3
MediaTek Inc (Taiwan)	2.9
Reliance Industries Ltd (India)	2.9
Sino Biopharmaceutical Ltd (China)	2.6
<b>TOTAL</b>	<b>43.5%</b>

Source: Artisan Partners. Portfolio country classifications are defined by the investment team.

## Sector Diversification (% of portfolio securities)

	Fund	MSCI EM <sup>1</sup>
Consumer Goods	7.6	8.0
Extractives & Minerals Processing	5.8	10.6
Financials	17.7	21.3
Food & Beverage	3.8	5.6
Health Care	6.7	4.4
Infrastructure	4.4	5.6
Renewable Resources & Alternative Energy	0.6	1.1
Resource Transformation	9.6	5.3
Services	3.2	1.1
Technology & Communications	39.6	31.6
Transportation	1.0	5.4
<b>TOTAL</b>	<b>100.0%</b>	<b>100.0%</b>

Source: Artisan Partners/SASB/MSCI. Cash and cash equivalents represented 6.4% of the total portfolio. <sup>1</sup>MSCI Emerging Markets Index.

## Region/Country Allocation (% of portfolio securities)

REGION	Fund	MSCI EM <sup>1</sup>
<b>EMERGING ASIA</b>	<b>70.5</b>	<b>78.8</b>
China	24.0	32.0
Taiwan	19.2	14.8
Korea	12.0	12.0
India	10.5	14.0
Indonesia	2.3	1.9
Malaysia	1.5	1.5
Thailand	0.7	1.9
Vietnam	0.4	—
<b>LATIN AMERICA</b>	<b>16.2</b>	<b>8.3</b>
Brazil	6.0	5.2
Argentina	4.9	—
Mexico	2.2	2.1
Chile	1.8	0.6
Peru	1.3	0.2
<b>EUROPE, MIDDLE EAST AND AFRICA</b>	<b>7.2</b>	<b>12.9</b>
South Africa	2.9	3.5
Greece	2.8	0.3
Kazakhstan	1.6	—
Russia	0.0	—
<b>DEVELOPED MARKETS</b>	<b>6.1</b>	<b>—</b>
Netherlands	2.7	—
Hong Kong	2.0	—
Portugal	0.8	—
Singapore	0.5	—
<b>TOTAL</b>	<b>100.0%</b>	<b>100.0%</b>

Source: Artisan Partners/MSCI. <sup>1</sup>MSCI Emerging Markets Index. Countries held in the index, but not held in the portfolio, are not listed. Portfolio country classifications are defined by the investment team and may differ substantially from MSCI classifications; index country classifications reflect MSCI methodology. For the portfolio's country breakdown according to MSCI methodology, refer to the Fund's most recent portfolio holdings at [www.sec.gov](http://www.sec.gov).

## Investment Team (Pictured left to right)



Portfolio Manager	Years of Investment Experience
Maria Negrete-Gruson, CFA	31
<b>Analysts</b>	
Meagan Nace, CFA	30
Chen Gu, CFA	34
Nicolas Rodriguez-Brizuela	23
Gurpreet Pal	18
Jessica Lin, CFA	17

Carefully consider the Fund's investment objective, risks and charges and expenses. This and other important information is contained in the Fund's prospectus and summary prospectus, which can be obtained by calling 800.344.1770. Read carefully before investing.

Current and future portfolio holdings are subject to risk. The value of portfolio securities selected by the investment team may rise or fall in response to company, market, economic, political, regulatory or other news, at times greater than the market or benchmark index. Investments in which the team has determined to have sustainable growth characteristics may underperform other securities and may not achieve their sustainable growth potential. A non-diversified portfolio may invest a larger portion of assets in securities of a smaller number of issuers and performance of a single issuer may affect overall portfolio performance greater than in a diversified portfolio. International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Such risks include new and rapidly changing political and economic structures, which may cause instability; underdeveloped securities markets; and higher likelihood of high levels of inflation, deflation or currency devaluations. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods.

MSCI Emerging Markets Index measures the performance of emerging markets. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

For the purpose of determining the Fund's holdings, securities of the same issuer are aggregated to determine the weight in the Fund. The discussion of portfolio holdings does not constitute a recommendation of any individual security. These holdings comprise the following percentages of the Fund's total net assets as of 31 Jul 2022: China Traditional Chinese Medicine Holdings Co Ltd 1.6%; MercadoLibre Inc 2.3%. As of 3 Mar 2022, Russian holdings are valued at zero. Securities named in the Commentary, but not listed as a Top Ten Holding or not listed here are not held in the Fund as of the date of this report. The portfolio managers' views and portfolio holdings are subject to change and the Fund disclaims any obligation to advise investors of such changes.

Unless otherwise indicated, all information in this report includes all classes of shares, except performance and expense ratio information, and is as of the date shown in the upper right hand corner. Totals may not sum due to rounding.

The Global Industry Classification Standard (GICS<sup>®</sup>) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

This material is provided for informational purposes without regard to your particular investment needs and shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein.

MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used to create indices or financial products. This report is not approved or produced by MSCI.

The Sustainable Industry Classification System (SICS<sup>®</sup>) is the exclusive intellectual property of Sustainability Accounting Standards Board (SASB). SICS is intended to group companies based on their shared sustainability-related risks and opportunities.

Sector exposure percentages reflect sector designations as currently classified by SICS.

Artisan Partners Funds offered through Artisan Partners Distributors LLC (APDLLC), member FINRA. APDLLC is a wholly owned broker/dealer subsidiary of Artisan Partners Holdings LP. Artisan Partners Limited Partnership, an investment advisory firm and adviser to Artisan Partners Funds, is wholly owned by Artisan Partners Holdings LP.

© 2022 Artisan Partners. All rights reserved.